Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012

For all but the TNFi and IL-1 blocking agents, there are too few data to draw any conclusions. Since a lack of association is extremely difficult to prove, no biological agents can be assumed to be safe. Other biological agents Alefacept Alefacept (approved in the USA for psoriasis but not PsA) is a...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of the rheumatic diseases 2013-04, Vol.72 (suppl 2), p.ii2-ii34
Hauptverfasser:	Furst, Daniel E, Keystone, Edward Clark, So, Alexander K, Braun, Jürgen, Breedveld, Ferry C, Burmester, Gerd R, De Benedetti, Fabrizio, Dörner, Thomas, Emery, Paul, Fleischmann, Roy, Gibofsky, Allan, Kalden, J R, Kavanaugh, Arthur, Kirkham, Bruce, Mease, Philip, Rubbert-Roth, A, Sieper, Joachim, Singer, Nora G, Smolen, Josef S, Van Riel, Piet L C M, Weisman, Michael H, Winthrop, Kevin L
Format:	Artikel
Sprache:	eng
Schlagworte:	Abatacept Anti-TNF Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - therapeutic use Antigens Antirheumatic Agents - adverse effects Antirheumatic Agents - therapeutic use Clinical medicine Clinical trials Disease FDA approval Female Humans Immunoconjugates - adverse effects Immunoconjugates - therapeutic use Immunosuppressive Agents - adverse effects Immunosuppressive Agents - therapeutic use Male Pain Patients Polyethylene Glycols - adverse effects Polyethylene Glycols - therapeutic use Pregnancy Psoriasis Rheumatic diseases Rheumatic Diseases - complications Rheumatic Diseases - drug therapy TNF-alpha Treatment Treatment Outcome Tumor Necrosis Factor-alpha - antagonists & inhibitors Urate Oxidase - adverse effects Urate Oxidase - therapeutic use Vaccines Working groups
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!